NCT06909136View on ClinicalTrials.gov

A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

May 15, 2028

Conditions
Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly
Interventions
DRUG

Ruxolitinib phosphate tablet（Jakavi,NOVARTIS,9104733)

5-20mg BID (dosage per investigator judgement,JAKi intolerable pts will receive recuded dose of RUX(≥ 5mg BID),and suboptimal JAKi response pts will receive RUX of 15-20 mg BID）

Trial Locations (1)

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Suzhou Junjing BioSciences Co., Ltd.

INDUSTRY

NCT06909136 - A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter